IBRX ImmunityBio Inc

Price (delayed)

$3.62

Market cap

$2.52B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.97

Enterprise value

$3.39B

NantKwest (NASDAQ: NK) is an innovative, clinical-stage, immunotherapy company focused on harnessing the power of the innate immune system to treat cancer and infectious diseases. NantKwest is the leading producer ...

Highlights
ImmunityBio's revenue has surged by 121% YoY
The company's gross profit has surged by 121% YoY
ImmunityBio's net income has decreased by 26% YoY
The debt rose by 22% year-on-year and by 12% since the previous quarter

Key stats

What are the main financial stats of IBRX
Market
Shares outstanding
696.53M
Market cap
$2.52B
Enterprise value
$3.39B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1,901.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,591.96
Earnings
Revenue
$1.31M
EBIT
-$454.03M
EBITDA
-$430.32M
Free cash flow
-$425.62M
Per share
EPS
-$0.97
Free cash flow per share
-$0.62
Book value per share
-$1.01
Revenue per share
$0
TBVPS
$0.62
Balance sheet
Total assets
$444.33M
Total liabilities
$1.14B
Debt
$998.94M
Equity
-$698.39M
Working capital
$180.72M
Liquidity
Debt to equity
-1.43
Current ratio
3.91
Quick ratio
3.54
Net debt/EBITDA
-2.02
Margins
EBITDA margin
-32,899%
Gross margin
100%
Net margin
-45,691.7%
Operating margin
-27,527.1%
Efficiency
Return on assets
-134.2%
Return on equity
N/A
Return on invested capital
-42.9%
Return on capital employed
-118.8%
Return on sales
-34,712.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IBRX stock price

How has the ImmunityBio stock price performed over time
Intraday
0%
1 week
-2.16%
1 month
-20.26%
1 year
135.06%
YTD
-27.89%
QTD
-42.72%

Financial performance

How have ImmunityBio's revenue and profit performed over time
Revenue
$1.31M
Gross profit
$1.31M
Operating income
-$360.05M
Net income
-$597.65M
Gross margin
100%
Net margin
-45,691.7%
ImmunityBio's revenue has surged by 121% YoY
The company's gross profit has surged by 121% YoY
The net margin has surged by 77% since the previous quarter and by 43% year-on-year
ImmunityBio's operating margin has soared by 76% from the previous quarter and by 56% YoY

Growth

What is ImmunityBio's growth rate over time

Valuation

What is ImmunityBio stock price valuation
P/E
N/A
P/B
N/A
P/S
1,901.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2,591.96
ImmunityBio's EPS has increased by 15% YoY and by 11% QoQ
ImmunityBio's equity has decreased by 9% YoY
ImmunityBio's revenue has surged by 121% YoY
The P/S is 64% less than the last 4 quarters average of 5225.7 and 60% less than the 5-year quarterly average of 4805.3

Efficiency

How efficient is ImmunityBio business performance
ImmunityBio's return on sales has surged by 77% QoQ and by 44% YoY
The company's return on invested capital rose by 35% YoY and by 21% QoQ
IBRX's return on assets is up by 9% since the previous quarter and by 4.3% year-on-year

Dividends

What is IBRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IBRX.

Financial health

How did ImmunityBio financials performed over time
The total assets is 61% less than the total liabilities
The total assets has soared by 53% YoY and by 11% from the previous quarter
ImmunityBio's total liabilities has increased by 22% YoY and by 4.6% from the previous quarter
The debt rose by 22% year-on-year and by 12% since the previous quarter
The company's debt to equity fell by 12% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.